Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2009-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/156802609788897826PMID 19689363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melanin-Concentrating Hormone Receptor-1 Antagonists as Antiobesity Therapeutics

  2012cited by this paper
• Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

  2009cited by this paper
• Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity.

  2008cited by this paper
• Adipose Tissue Hormones and the Regulation of Food Intake

  2008cited by this paper
• Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators.

  2008cited by this paper
• Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.

  2008cited by this paper
• CNTF: a target therapeutic for obesity-related metabolic disease?

  2008cited by this paper
• Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.

  2008cited by this paper
• Cetilistat, a new lipase inhibitor for the treatment of obesity.

  2008cited by this paper
• Small-Molecule Melanin-Concentrating Hormone-1 Receptor Antagonists Require Brain Penetration for Inhibition of Food Intake and Reduction in Body Weight

  2008cited by this paper
• Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.

  2008cited by this paper
• Peptide ligands for the melanin-concentrating hormone (MCH) receptor 1.

  2007cited by this paper
• Melanocortin-4 receptor agonists for the treatment of obesity.

  2007cited by this paper
• Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists.

  2007cited by this paper
• Small molecule ligands of the human melanocortin-4 receptor.

  2007cited by this paper
• Biphenyl amides and isosteres as MCH R1 antagonists.

  2007cited by this paper
• Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.

  2007cited by this paper
• Recent progress toward nonpeptide ligands for the melanocortin-4 receptor.

  2007cited by this paper
• Pyrrolidines as potent functional agonists of the human melanocortin-4 receptor.

  2007cited by this paper
• Melanocortin subtype 4 receptor agonists: structure-activity relationships about the 4-alkyl piperidine core.

  2007cited by this paper
• Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1-R) antagonists.

  2007cited by this paper
• Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit.

  2007cited by this paper
• Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists.

  2007cited by this paper
• MCH-R1 antagonists: what is keeping most research programs away from the clinic?

  2007cited by this paper
• Challenges in the Discovery and Development of New Agents for the Treatment of Obesity

  2007cited by this paper
• An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.

  2007cited by this paper
• Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists.

  2007cited by this paper
• Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.

  2007cited by this paper
• Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.

  2007cited by this paper
• Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists.

  2007cited by this paper
• SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: taming hERG.

  2007cited by this paper
• Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor.

  2007cited by this paper
• Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists.

  2007cited by this paper
• Thienopyrimidinone bis-aminopyrrolidine ureas as potent melanin-concentrating hormone receptor-1 (MCH-R1) antagonists.

  2007cited by this paper
• Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity

  2007cited by this paper
• Melanin concentrating hormone receptor antagonists as antiobesity agents: from M2 to MCHR-1.

  2007cited by this paper
• Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists.

  2007cited by this paper
• Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2.

  2006cited by this paper
• Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.

  2006cited by this paper
• Privileged structure based ligands for melanocortin receptors--4,4-disubstituted piperidine derivatives.

  2006cited by this paper
• Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1.

  2006cited by this paper
• Prevalence of overweight and obesity in the United States, 1999-2004.

  2006cited by this paper
• Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists.

  2006cited by this paper
• Does Obesity Induce Resistance to the Long-Term Cardiovascular and Metabolic Actions of Melanocortin 3/4 Receptor Activation?

  2006cited by this paper
• Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

  2006cited by this paper
• Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.

  2006cited by this paper
• Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• Novel benzimidazole-based MCH R1 antagonists.

  2006cited by this paper
• Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters

  2006cited by this paper
• Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity.

  2006cited by this paper
• Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions.

  2006cited by this paper
• Emerging therapeutic strategies for obesity.

  2006cited by this paper
• A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties.

  2006cited by this paper
• Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• 6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist.

  2006cited by this paper
• Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents.

  2006cited by this paper
• Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.

  2006cited by this paper
• Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity.

  2006cited by this paper
• Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists.

  2006cited by this paper
• Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases.

  2006cited by this paper
• Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas.

  2006cited by this paper
• SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849.

  2006cited by this paper
• Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849.

  2006cited by this paper
• Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: impacting hERG liability via aryl modifications.

  2006cited by this paper
• Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• Tetrahydroisoquinolines as MCH-R1 antagonists.

  2006cited by this paper
• The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.

  2006cited by this paper
• Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).

  2005cited by this paper
• Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.

  2005cited by this paper
• Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.

  2005cited by this paper
• Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.

  2005cited by this paper
• Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.

  2005cited by this paper
• Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides.

  2005cited by this paper
• Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics.

  2005cited by this paper
• Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline.

  2005cited by this paper
• Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines.

  2005cited by this paper
• Discovery and SAR of 4-amino-2-biarylbutylurea MCH 1 receptor antagonists through solid-phase parallel synthesis.

  2005cited by this paper
• Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists.

  2005cited by this paper
• Discovery and SAR of biaryl piperidine MCH1 receptor antagonists through solid-phase encoded combinatorial synthesis.

  2005cited by this paper
• Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists.

  2005cited by this paper
• Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.

  2005cited by this paper
• 1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.

  2005cited by this paper
• Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.

  2005cited by this paper
• 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists.

  2005cited by this paper
• Structure-activity relationship studies on a series of cyclohexylpiperazines bearing a phanylacetamide as ligands of the human melanocortin-4 receptor.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives.

  2005cited by this paper
• 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists.

  2005cited by this paper
• WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity

  2005cited by this paper
• A review of melanocortin receptor small molecule ligands.

  2005cited by this paper
• Identification of aminopiperidine benzamides as MCHr1 antagonists.

  2005cited by this paper
• Privileged structure-based ligands for melanocortin receptors-tetrahydroquinolines, indoles, and aminotetralines.

  2005cited by this paper
• Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists.

  2005cited by this paper
• Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.

  2005cited by this paper
• Melanocortin ligands: 30 years of structure–activity relationship (SAR) studies

  2004cited by this paper
• Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution.

  2004cited by this paper
• Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1).

  2004cited by this paper
• Peptide YY and appetite control.

  2004cited by this paper

• Therapeutic strategies against metabolic imbalance in a male mouse model with 5-HT2CR loss-of-function.

  2024cites this paper
• The melanocortin action is biased toward protection from weight loss in mice

  2023cites this paper
• Insulin-Sensitizer Effects of Fenugreek Seeds in Parallel with Changes in Plasma MCH Levels in Healthy Volunteers

  2018influential citation
• Lipid accumulation by oleaginous and non-oleaginous yeast strains in nitrogen and phosphate limitation

  2016cites this paper
• Quinazoline pharmacophore in therapeutic medicine

  2016cites this paper
• Effect of short and long-term treatment with antipsychotics on orexigenic/anorexigenic neuropeptides expression in the rat hypothalamus.

  2015cites this paper
• Future management of human obesity: understanding the meaning of genetic susceptibility

  2014cites this paper
• Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists.

  2013cites this paper
• 2‐Heteroaryl Benzimidazole Derivatives as Melanin Concentrating Hormone Receptor 1 (MCH‐R1) Antagonists.

  2013cites this paper
• 4-Aminophthalazin-1(2H)-one Derivatives as Melanin Concentrating Hormone Receptor 1 (MCH-R1) Antagonists

  2013cites this paper
• Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models

  2013cites this paper
• 4-Heteroaryl Phthalazin-1(2H)-one Derivatives as Potent Melanin Concentrating Hormone Receptor 1 (MCH-R1) Antagonists

  2012cites this paper
• 4-arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1).

  2012cites this paper
• Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?

  2012cites this paper
• Tratamiento farmacológico de la obesidad

  2012cites this paper
• Synthesis and SAR investigations of novel 2-arylbenzimidazole derivatives as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists.

  2011cites this paper
• Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists

  2011cites this paper
• Pharmacological management of appetite expression in obesity

  2010cites this paper
• Pharmacologic therapies for obesity.

  2010cites this paper
• Current and Future Drug Targets in Weight Management

  2010cites this paper
• Pharmacologic Therapies for Obesity

  year unknowncites this paper